Suppr超能文献

头孢洛扎/他唑巴坦对来自五个拉丁美洲国家的[具体细菌名称缺失]临床分离株的体外活性比较

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of and from Five Latin American Countries.

作者信息

García-Betancur Juan Carlos, De La Cadena Elsa, Mojica María F, Hernández-Gómez Cristhian, Correa Adriana, Radice Marcela A, Castañeda-Méndez Paulo, Jaime-Villalon Diego A, Gales Ana C, Munita José M, Villegas María Virginia

机构信息

Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria, Universidad El Bosque, Bogotá 110121, Colombia.

Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-7164, USA.

出版信息

Antibiotics (Basel). 2022 Aug 13;11(8):1101. doi: 10.3390/antibiotics11081101.

DOI:10.3390/antibiotics11081101
PMID:36009970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9405202/
Abstract

BACKGROUND

Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of and collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents.

METHODS

a total of 2760 clinical isolates (508 and 2252 ) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines.

RESULTS

according to the CLSI breakpoints, 68.1% (346/508) of and 83.9% (1889/2252) of isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against , and its performance in vitro was comparable to fosfomycin. When tested against , it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem.

CONCLUSIONS

these results show that C/T is an active β-lactam agent against clinical isolates of and .

摘要

背景

头孢他啶/阿维巴坦（C/T）是一种抗假单胞菌氧亚氨基氨噻唑基头孢菌素与具有强大体外活性的已知β-内酰胺酶抑制剂阿维巴坦的组合。本研究的目的是评估C/T对2016年至2017年从五个拉丁美洲国家收集的临床分离株的活性，这是在其于拉丁美洲临床使用之前，并将其与其他可用的广谱抗菌药物的活性进行比较。

方法

从20家医院连续收集了总共2760株临床分离株（508株肺炎克雷伯菌和2252株大肠埃希菌），并按照现行指南对C/T和对照药物的敏感性进行了测试和解读。

结果

根据CLSI标准，68.1%（346/508）的肺炎克雷伯菌和83.9%（1889/2252）的大肠埃希菌分离株对C/T敏感。总体而言，在针对肺炎克雷伯菌进行测试时，C/T显示出比目前可用的头孢菌素、哌拉西林/他唑巴坦和碳青霉烯类更高的体外活性，并且其体外表现与磷霉素相当。在针对大肠埃希菌进行测试时，它显示出比头孢菌素和哌拉西林/他唑巴坦更高的活性，与厄他培南的活性相似。

结论

这些结果表明，C/T是一种对肺炎克雷伯菌和大肠埃希菌临床分离株有效的β-内酰胺类药物。

相似文献

1
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of and from Five Latin American Countries.
Antibiotics (Basel). 2022 Aug 13;11(8):1101. doi: 10.3390/antibiotics11081101.
2
Ceftolozane/Tazobactam Activity Against Drug-Resistant and Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018).
Infect Drug Resist. 2022 Nov 22;15:6739-6753. doi: 10.2147/IDR.S387097. eCollection 2022.
3
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).
Braz J Infect Dis. 2017 Nov-Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.
4
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
5
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17.
6
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
J Glob Antimicrob Resist. 2020 Jun;21:60-64. doi: 10.1016/j.jgar.2019.10.009. Epub 2019 Oct 21.
7
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
8
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21.
JAC Antimicrob Resist. 2023 Aug 11;5(4):dlad098. doi: 10.1093/jacamr/dlad098. eCollection 2023 Aug.
9
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.
10
Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
J Med Microbiol. 2022 Apr;71(4). doi: 10.1099/jmm.0.001487.

引用本文的文献

1
Mutational Analysis of Colistin-Resistant Isolates: From Genomic Background to Antibiotic Resistance.
Pathogens. 2025 Apr 15;14(4):387. doi: 10.3390/pathogens14040387.
2
Impact of Antimicrobial Therapy on Mortality and Readmission in Multidrug-Resistant Pseudomonas Infections: A Retrospective Study at Dammam Medical Complex.
Cureus. 2024 Nov 30;16(11):e74870. doi: 10.7759/cureus.74870. eCollection 2024 Nov.
3
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
JAC Antimicrob Resist. 2024 May 24;6(3):dlae077. doi: 10.1093/jacamr/dlae077. eCollection 2024 Jun.
4
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant But Not against Isolates.
Medicina (Kaunas). 2023 Mar 7;59(3):518. doi: 10.3390/medicina59030518.
5
Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals.
Antibiotics (Basel). 2022 Dec 28;12(1):52. doi: 10.3390/antibiotics12010052.
6
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of from five Latin American countries.
Front Microbiol. 2022 Oct 24;13:1035609. doi: 10.3389/fmicb.2022.1035609. eCollection 2022.

本文引用的文献

1
New Drugs for the Treatment of Infections with Limited Treatment Options: A Narrative Review.
Antibiotics (Basel). 2022 Apr 26;11(5):579. doi: 10.3390/antibiotics11050579.
2
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa.
Infect Dis Ther. 2022 Apr;11(2):661-682. doi: 10.1007/s40121-022-00591-2. Epub 2022 Feb 12.
3
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.
Open Forum Infect Dis. 2021 Jun 16;8(7):ofab320. doi: 10.1093/ofid/ofab320. eCollection 2021 Jul.
4
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
BMC Microbiol. 2021 Mar 6;21(1):74. doi: 10.1186/s12866-021-02135-z.
5
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa.
mSphere. 2021 Jan 27;6(1):e01026-20. doi: 10.1128/mSphere.01026-20.
6
Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01117-20.
7
Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients - a tertiary care centre experience.
Access Microbiol. 2020 Sep 3;2(10):acmi000163. doi: 10.1099/acmi.0.000163. eCollection 2020.
8
Update on the epidemiology of carbapenemases in Latin America and the Caribbean.
Expert Rev Anti Infect Ther. 2021 Feb;19(2):197-213. doi: 10.1080/14787210.2020.1813023. Epub 2020 Sep 11.
9
Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
J Glob Antimicrob Resist. 2020 Sep;22:689-694. doi: 10.1016/j.jgar.2020.04.017. Epub 2020 Apr 27.
10
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec;38(10):474-478. doi: 10.1016/j.eimc.2020.01.017. Epub 2020 Mar 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验